CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy. (February 2021)
- Record Type:
- Journal Article
- Title:
- CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy. (February 2021)
- Main Title:
- CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy
- Authors:
- Rosen, Benjamin S.
Wilkie, Joel R.
Sun, Yilun
Ibrahim, Mohannad
Casper, Keith A.
Miller, Jessa E.
Chotchutipan, Thong
Stucken, Chaz L.
Bradford, Carol
Prince, Mark E.P.
Rosko, Andrew J.
Malloy, Kelly M.
McLean, Scott A.
Chinn, Steven B.
Shuman, Andrew G.
Spector, Matthew E.
Swiecicki, Paul L.
Worden, Francis P.
Shah, Jennifer L.
Schonewolf, Caitlin A.
Chapman, Christina H.
Eisbruch, Avraham
Mierzwa, Michelle L. - Abstract:
- Highlights: CT and PET imaging features are associated with oropharynx cancer treatment efficacy. Extra nodal extension strongly predicts early failure in low-risk patients. Pre-treatment imaging should guide cancer therapy de-escalation regimens. Abstract: Purpose: To assess associations between imaging biomarkers from standard of care pre-treatment CT and FDG-PET scans and locoregional (LR) and distant metastatic (DM) recurrences in patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiotherapy (CRT). Methods: An institutional database from a single NCI-designated cancer center identified 266 patients with p16+ OPSCC treated with definitive CRT in our department from 2005 to 2016 with evaluable pre-treatment FDG-PET scans. Quantitative SUV metrics and qualitative imaging metrics were determined from FDG-PET and CT scans, while clinical characteristics were abstracted from the medical record. Associations between clinical/imaging features and time to LR (TTLRF) or DM (TTDMF) failure and overall survival (OS) were assessed using univariable Cox regression and penalized stepwise regression for multivariable analyses (MVA). Results: There were 27 LR and 32 DM recurrences as incident failures. Imaging biomarkers were significantly associated with TTLRF, TTDMF and OS. FDG-PET metrics outperformed CT and clinical metrics for TTLRF, with metabolic tumor volume being the only significant feature selected on MVA: C-index = 0.68 ( pHighlights: CT and PET imaging features are associated with oropharynx cancer treatment efficacy. Extra nodal extension strongly predicts early failure in low-risk patients. Pre-treatment imaging should guide cancer therapy de-escalation regimens. Abstract: Purpose: To assess associations between imaging biomarkers from standard of care pre-treatment CT and FDG-PET scans and locoregional (LR) and distant metastatic (DM) recurrences in patients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiotherapy (CRT). Methods: An institutional database from a single NCI-designated cancer center identified 266 patients with p16+ OPSCC treated with definitive CRT in our department from 2005 to 2016 with evaluable pre-treatment FDG-PET scans. Quantitative SUV metrics and qualitative imaging metrics were determined from FDG-PET and CT scans, while clinical characteristics were abstracted from the medical record. Associations between clinical/imaging features and time to LR (TTLRF) or DM (TTDMF) failure and overall survival (OS) were assessed using univariable Cox regression and penalized stepwise regression for multivariable analyses (MVA). Results: There were 27 LR and 32 DM recurrences as incident failures. Imaging biomarkers were significantly associated with TTLRF, TTDMF and OS. FDG-PET metrics outperformed CT and clinical metrics for TTLRF, with metabolic tumor volume being the only significant feature selected on MVA: C-index = 0.68 ( p = 0.01). Radiographic extranodal extension (rENE), positive retropharyngeal nodes (RPN+), and clinical stage were significant on MVA for TTDMF: C-index = 0.84 ( p < 0.001). rENE, group stage, and RPN+ were significant on MVA for OS: C-index = 0.77 ( p < 0.001). Conclusions: In the largest study to date of uniformly treated patients with CRT to evaluate both pretreatment CT and FDG-PET, radiographic biomarkers were significantly associated with TTLRF, TTDMF and OS among patients with p16+ OPSCC treated with CRT. CT metrics performed best to predict TTDMF, while FDG-PET metrics showed improved prediction for LRRFS. These metrics may help identify candidates for treatment intensification or de-escalation of therapy. Statement of translational relevance: Pre-treatment imaging features from standard-of-care PET/CT imaging show promise for predicting long-term outcomes following HPV-associated oropharynx cancer (HPV-OPC) therapy. This study comprehensively characterizes qualitative and quantitative pre-treatment imaging metrics associated with time to pattern-specific failure in a cohort of 266 patients treated uniformly with definitive chemoradiation. Multivariate analysis (MVA) for time to locoregional failure (TTLRF), time to distant metastatic failure (TTDMF), and overall survival (OS) was performed. FDG-PET metrics outperformed CT and clinical metrics for TTLRF. CT radiographic extranodal extension, positive retropharyngeal nodes, and stage strongly predicted TTDMF (combined C-index = 0.84, log rank p < 0.001). Number of smoking pack-years complemented clinical and imaging features only in patients without radiographic extranodal extension or positive retropharyngeal nodes. Time to pattern-specific failure is important for guiding treatment de-escalation strategies, which intend to reduce treatment-related toxicity in patients with relatively long expected survival times. This study suggests that PET/CT features should play a crucial role in future de-escalation trials and management of HPV-OPC patients. … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 155(2021)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 155(2021)
- Issue Display:
- Volume 155, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 155
- Issue:
- 2021
- Issue Sort Value:
- 2021-0155-2021-0000
- Page Start:
- 174
- Page End:
- 181
- Publication Date:
- 2021-02
- Subjects:
- Imaging biomarkers -- HPV cancers -- Oropharynx -- FDG-PET -- Computed tomography
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2020.10.006 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16190.xml